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http://dx.doi.org/10.1016/j.ccell.2015.05.004SUMMARYFrom an shRNA screen, we identified ClpP as a member of the mitochondrial proteome whose knockdown
reduced the viability of K562 leukemic cells. Expression of this mitochondrial protease that has structural
similarity to the cytoplasmic proteosome is increased in leukemic cells from approximately half of all patients
with AML. Genetic or chemical inhibition of ClpP killed cells from both human AML cell lines and primary
samples in which the cells showed elevated ClpP expression but did not affect their normal counterparts.
Importantly, Clpp knockout mice were viable with normal hematopoiesis. Mechanistically, we found that
ClpP interacts with mitochondrial respiratory chain proteins and metabolic enzymes, and knockdown of
ClpP in leukemic cells inhibited oxidative phosphorylation and mitochondrial metabolism.INTRODUCTION
The cytoplasmic/nuclear proteasome complex is a well recog-
nized therapeutic target, and proteasome inhibitors have been
approved for the treatment of hematologic malignancies (Fisher
et al., 2006; O’Connor et al., 2009; Richardson et al., 2005; Vij
et al., 2012). Mitochondria also possess a serine protease
complex, ClpP, that is structurally similar to the cytoplasmic/Significance
Perturbations in the cytoplasmic and nuclear proteasome are k
but the importance of ClpP, a mitochondrial protease with st
lished. We have now shown that loss of ClpP does not impact
leukemic cells, including those with stem and progenitor activ
stress and a greater reliance on oxidative phosphorylation. Th
be an attractive therapeutic strategy for a subset of human ac
864 Cancer Cell 27, 864–876, June 8, 2015 ª2015 Elsevier Inc.nuclear proteasome (Goard and Schimmer, 2014), but little is
known about the expression of this complex or the effects of
its inhibition in malignant cells.
ClpP is encoded by a nuclear gene, translated in the cyto-
plasm, and imported into the mitochondrial matrix. There it is
assembled into a tetradecamer consisting of seven repeated
symmetric rings arranged in a stable double-ringed structure
(Corydon et al., 1998; de Sagarra et al., 1999), each end of whichnown to contribute to the acquisition ofmalignant properties,
ructural homology to the proteasome, has not been estab-
normal hematopoiesis, whereas ClpP inhibition kills human
ity, which may be attributable to their higher mitochondrial
ese results suggest that targeting mitochondrial ClpP may
ute leukemias.
is capped by an AAA+ ATPase chaperone, ClpX (Kang et al.,
2005). Based on studies of its homologs in bacteria and its
structural similarities to the cytoplasmic proteasome, the ClpP
complex is thought to degrade damaged or misfolded proteins
inside mitochondria.
Inhibition of ClpP in normal mice (Gispert et al., 2013), hu-
mans (Jenkinson et al., 2013), and C. elegans (Haynes et al.,
2007, 2010) has not been found to elicit much loss of viability.
For example, Clpp/ mice are viable but display infertility,
slight growth retardation, and acquired hearing loss (Gispert
et al., 2013). Homozygous CLPP mutations have also been
described in individuals from three human families (Jenkinson
et al., 2013). Similar to the mouse phenotype, these individuals
have congenital hearing loss and premature ovarian failure.
In contrast, deregulating ClpP activity in certain bacteria,
either through inhibition (Zeiler et al., 2012) or increased
activation (Conlon et al., 2013), is cytotoxic even when they
are dormant or have acquired antibiotic resistance (Conlon
et al., 2013).
Recently, we (Skrtic et al., 2011) and others (Lagadinou et al.,
2013) demonstrated that leukemic cells, including those with
stem and progenitor activity from patients with acute myeloid
leukemia (AML) have an increased mitochondrial mass and
reliance on oxidative phosphorylation. We therefore initiated a
study to identify members of the mitochondrial proteome whose
inhibition might reduce the viability of AML cells.
RESULTS
A Genetic Screen Identifies ClpP as Essential for the
Viability of Leukemia Cells
We first sought to determine whether short hairpin RNA
(shRNA)-mediated knockdown of any of the 1,300 members
of the mitochondrial proteome would identify candidates that
could reduce the viability of human leukemic cells using K562
cells as targets. Accordingly, we transduced K562 cells with
a library of 54,021 shRNAs in barcoded lentiviral vectors target-
ing 11,255 nuclearly encoded genes. Twenty-one days after
transduction, cells were harvested, genomic DNA was isolated,
and the relative abundance of shRNA sequences present in the
surviving cells was determined by array analysis of the barco-
des. shRNAs able to reduce the viability or growth of K562 cells
were inferred to be those not represented in the final cell
population (Figure S1A). shRNAs targeting BCR and ABL1
were top hits (Figures S1A–S1C), therefore validating the
robustness of the screen because K562 cells are dependent
on the BCR-ABL1 fusion oncoprotein for survival (Dan et al.,
1998). In this screen, 2,422 shRNAs targeted 496 members of
the mitochondrial proteome, and of the top 25 targets, four
were mitochondrial proteases (NLN, ClpP, PARL, and PITRM1),
with two targeting ClpP ranking in the top 1% of all hits in the
screen (Figures 1A–1C). In contrast, the mitochondrial matrix
protease Lon did not appear as a hit in our shRNA screen,
and repetition of this experiment using shRNAs that produced
high levels of target knockdown (both protein and mRNA)
confirmed that Lon was not required for the growth and viability
of TEX, OCI-AML2, or K562 leukemia cells (Figure S1D and
data not shown). Therefore, some, but not all, mitochondrial
proteases are necessary for the viability of AML cells.ClpP Is Overexpressed in a Subset of AML Cells and
Patient Samples
To investigate ClpP further as a therapeutic target in human
AML, we measured ClpP protein expression in 511 primary
AML samples and CD34+ cells from 21 healthy individuals
using reverse-phase protein array. Compared with normal
CD34+ hematopoietic progenitor cells, ClpP was overex-
pressed in 45% of the primary AML samples (Figure 1D).
Elevated ClpP was not correlated with CD34 expression based
on flow cytometry, remission attainment, overall or event-free
survival, or remission duration (Figures S1E–S1G and data
not shown). Increased expression of ClpP also showed no
association with any morphologic subtype, cytogenetic risk
group, or mutational profile (Figures 1E and 1F; Figures
S1H–S1M).
Increased expression of ClpP in a subset of AML cell lines
and patient samples was confirmed by immunoblotting (Fig-
ure 1G; Figure S1N). In addition, we demonstrated that CLPP
mRNA was increased in a subset of AML cells compared
with normal hematopoietic cells and expressed similarly in
the bulk and progenitor (CD34+CD38) populations of primary
AML samples (Figure S1O). Gene expression analysis of previ-
ously characterized AML patient samples demonstrated that
CLPP mRNA was similarly expressed in fractions enriched or
depleted of leukemic stem cells (LSCs) defined by functional
assays (p = 0.45) (Figure S1P). Analysis of TCGA data indicated
that CLPP expression did not correlate with known AML muta-
tions (Table S1).
In primary AML patient samples, higher CLPP expression was
associated with an increased expression of genes related to the
mitochondrial unfolded protein response (mtUPR). This positive
correlation was observed in both the LSC+ and LSC fractions of
primary AML cells (Figures S1Q and S1R). Therefore, increased
ClpP may be a marker of increased mitochondrial stress in a
subset of AML patients that is downstream of multiple genetic
pathways.
Analysis of the Cancer Cell Line Encyclopedia indicated that
CLPP was highly expressed in AML cells but also increased
in subsets of other hematologic malignancies, including multi-
ple myeloma, various lymphomas, and chronic myeloid leuke-
mia (CML). In addition, CLPP was highly expressed in solid
tumors such as prostate cancer and sarcomas (Figure S1S).
Therefore, ClpP may also be a relevant target for malignancies
beyond AML.
Genetic Knockdown of ClpP Reduces the Growth and
Viability of AML Cells with High ClpP Expression
Wenext tested the effects of ClpP knockdown on the growth and
viability of AML cells. K562, TEX, OCI-AML2, and HL60 cells
were transduced with lentiviral vectors expressing a control
sequence or three independent shRNA sequences targeting
CLPP. The shRNA sequences targeting CLPP showed robust
target knockdown by both quantitative RT-PCR and immuno-
blotting (Figures 2A–2D and data not shown). Knockdown of
ClpP reduced the growth and viability of the K562, TEX, and
OCI-AML2 cells that have high ClpP expression (Figures 2A–
2C) but not HL60 cells that express low basal levels of ClpP
(Figure 2D). In addition, knockdown of ClpP in TEX cells
reduced engraftment into the marrow of non-obese diabeticCancer Cell 27, 864–876, June 8, 2015 ª2015 Elsevier Inc. 865
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Figure 1. A Genetic Screen Identifies ClpP as Essential for the Viability of Leukemia Cells
(A) The list of top 25 shRNAs targeting the mitochondrial proteome. Max, maximum.
(B) The percent depletion in rank order of the 2,422 shRNAs targeting 496 members of the mitochondrial proteome.
(C) The percent depletion of individual clones in the library targeting ClpP.
(D) Expression of ClpP measured in total cell lysates from 511 primary AML cases and 21 samples of normal CD34+ hematopoietic cells using a reverse-phase
protein array.
(E and F) Expression of ClpP in primary AML cases classified based on their morphologic French American British (FAB) subtype (E) or cytogenetic
abnormalities (F).
(G) Expression of ClpP protein in total cell lysates prepared from normal hematopoietic cells, primary AML samples, and indicated cell lines by immunoblotting.
Error bars represent SD. The box represents the first and third quartiles, whiskers represent the range, the center line represents the median, and the circles
represent outliers. See also Figure S1 and Table S1.
866 Cancer Cell 27, 864–876, June 8, 2015 ª2015 Elsevier Inc.
CA
B
D
E
Figure 2. Knockdown of ClpP Reduces the
Growth and Viability of AML Cells
(A–D) The expression of ClpP and Actin in TEX (A),
OCI-AML2 (B), K562 (C), and HL60 (D) cells 4 days
after transduction with lentiviral vectors express-
ing control shRNA or one of the three shRNAs
targeting ClpP were detected by immunoblotting.
Viable cell counts of cells seeded 4 days after
transduction are shown as mean ± SD. One of
three representative experiments is shown.
(E) The percentage of human CD45+ cells in the
non-injected femur of sublethally irradiated NOD/
SCID-GF mice determined by flow cytometry
(n = 10/group). **p = 0.005 by t test. The bar rep-
resents mean engraftment.(NOD)/severe combined immunodeficiency-growth factor
(SCID-GF) mice (Figure 2E).
Clpp Knockout Mice Are Viable with Normal
Hematopoiesis
To assess the effects of ClpP inhibition on normal hematopoiesis
in vivo, we created constitutive ClpP-deficient mice. In wild-type
(WT) mice, ClpP protein was expressed at low levels in the bone
marrow, lung, kidney, and stomach but was more abundant in
the pancreas, colon, testis, brain, and liver (Figure S2A). ClpP
was absent in all tested tissues from Clpp/ mice (Figure S2B).Cancer Cell 27, 864–Clpp/ mice are viable, although slightly
smaller than their WT counterparts (Fig-
ures S2C and S2D). Therefore, our mice
are similar to those obtained by Gispert
et al. (2013), who reported that 80%
of their Clpp/ mice survived over
400 days but were infertile and had
impaired hearing.
The study by Gispert et al. (2013) did
not report the effects of Clpp deficiency
on hematopoiesis. We therefore stud-
ied hematopoiesis in our Clpp/ mice.
Clpp/ mice had normal numbers of all
mature blood cell types in the circulation
(Figure 3A) and normal numbers of
phenotypically defined (LincKit+Sca1+)
progenitor cells in the bone marrow (Fig-
ure 3B). In vitro colony assays confirmed
the presence of equal numbers of pro-
genitors in the bone marrow of WT and
Clpp/ mice (Figure 3C). Likewise, cells
from the marrow of Clpp/ and WT
mice had a similar ability to repopulate
the marrow of sublethally irradiated con-
genicW41/W41 recipients when assessed
in a competitive repopulation assay (Fig-
ure 3D). T and B cell function and the
number of natural killer (NK) cells were
also similar in Clpp/ and WT mice (Fig-
ures S2E–S2G). p16 expression in T cells
from Clpp/ and WT mice was also
similar (Figure S2H). This lack of anydetectable effect of Clpp absence in murine hematopoiesis
supports the potential feasibility of using ClpP inhibitors for the
treatment of AML.
ClpP Interacts with Respiratory Chain Proteins and
Mitochondrial Metabolism Enzymes
The function and substrates of mammalian ClpP are largely
unknown. To gain insight into ClpP function, we used the BioID-
mass spectrometry (BioID-MS) method to identify ClpP-interact-
ing partners (Roux et al., 2012). To identify interacting proteins
using BioID-MS, a protein of interest is fused in-frame with a876, June 8, 2015 ª2015 Elsevier Inc. 867
WT Clpp -/-
0
50
100
150
200
H
b 
(g
/L
)
WT Clpp -/-
0
1000
2000
3000
4000
P
LT
 (x
10
9 /L
)
WT Clpp -/-
0
2
4
6
8
W
B
C
 (1
x1
09
/L
)
A
WT Clpp -/-
0.0
2.5
5.0
7.5
10.0
%
 L
in
-  c
K
it+
 S
ca
1+
 c
el
ls
B
1 2 3 4
0
50
100
150
200
250
BFU-E
CFU-GM
Clpp -/- WT
# 
co
lo
ni
es
/5
x1
04
 c
el
ls
 p
la
te
dC
D
100
75
50
25
0D
on
or
 c
hi
m
er
is
m
(%
)
Clpp+/+
Clpp-/- 1
Clpp-/- 2
Clpp-/- 3
T
%
 L
in
- c
K
it+
S
ca
1+
ce
lls
.
-/-
Figure 3. ClpP Knockout Mice Are Viable
with Normal Hematopoiesis
(A) Mean ± SD hemoglobin (Hb), platelet (PLT), and
WBC counts from peripheral blood samples of WT
and Clpp/ mice (n = 4/group).
(B) The frequency of LincKit+Sca1+ hematopoi-
etic cells in the bone marrow of WT and Clpp/
mice. Mean ± SD percentages were determined
by flow cytometry.
(C) Erythroid and myeloid colony formation from
burst-forming unit-erythroid (BFU-E) and colony-
forming unit-granulocyte, monocyte (CFU-GM) of
hematopoietic cells from WT and Clpp/ mice
(n = 3/group) plated in vitro under standard con-
ditions. Mean ± SD colony counts are shown.
(D) The mean ± SD proportions of CD45.2 cells
from WT or Clpp/ mice transplanted in suble-
thally irradiated congenic W41/W41 CD45.1 mice
measured by flow cytometry.
See also Figure S2.mutant E. coli biotin conjugating enzyme, BirA R118G (or BirA*).
BirA* efficiently activates biotin but exhibits a reduced affinity for
the activated molecule. Biotinoyl-AMP, therefore, simply dif-
fuses away from BirA* and reacts with nearby amine groups,
including those present on lysine residues in neighboring poly-
peptides. Following stringent cell lysis, biotinylated proteins
can be affinity-purified and identified using mass spectrometry.
From this protein interaction screen, we identified 191 mito-
chondrial ClpP-interacting proteins, 49 of which preferentially
interacted with WT or mutant ClpP over the unrelated mitochon-
drial matrix enzyme ornithine transcarbamoylase (OTC) (>3-fold
spectral counts for BirA*-ClpP versus BirA*-OTC; Figure 4A; Ta-
ble S2). The proteins interacting with WT and mutant ClpP were
similar. ClpX, the known regulatory subunit of ClpP, was the top
hit in our interactome map. Most of the 48 other preferential
ClpP-interacting proteins were components of the respiratory
chain or enzymes involved in mitochondrial metabolism. There-
fore, these data suggested that ClpP function could be important
to maintain the integrity of mitochondrial metabolism.
Inhibition of ClpP Impairs Oxidative Phosphorylation
Given the interactions of ClpPwith respiratory chain proteins and
metabolic enzymes, we evaluated the effects of ClpP inhibition
on oxidative phosphorylation. We found that knockdown of
ClpP reduced basal oxygen consumption in OCI-AML2 cells
(Figure 4B).
Succinate dehydrogenase subunit A (SDHA), a subunit of res-
piratory chain complex II, was a top hit in our interactionmapping868 Cancer Cell 27, 864–876, June 8, 2015 ª2015 Elsevier Inc.experiment. Therefore, we alsomeasured
the effects of ClpP inhibition on the activ-
ity of respiratory chain complex II. Knock-
down of ClpP reduced the enzymatic
activity of complex II in OCI-AML2 cells
(Figure 4C). Consistent with impaired
complex II activity, knockdown of ClpP
also increased mitochondrial reactive
oxygen species (ROS) production (Fig-
ure 4D). Using non-denaturing gels and
immunoblotting, we also observed fastermigrating bands of SDHA after ClpP knockdown, potentially
representing the accumulation of non-functional misfolded or
degraded SDHA (Figure 4E).
To determine whether the changes in oxidative phosphor-
ylation were functionally important for cell death after ClpP
inhibition, we examined the impact of ClpP inhibition in Rho (0)
cells that lackmitochondrial DNA and oxidative phosphorylation.
We knocked down ClpP in WT and Rho (0) 143B cells that
expressed similar levels of ClpP protein (Figures 4F–4H). ClpP
knockdown reduced the growth and viability of WT 143B cells
but had less effect on the growth and viability of Rho (0) cells (Fig-
ure 4I). In addition, we evaluated the impact of knocking down
SDHA in OCI-AML2 cells. Knockdown of SDHA impaired
complex II activity and reduced the growth and viability in these
cells (Figures S3A–S3C). Therefore, these results support SDHA
as a functionally important substrate for ClpP and a role for ClpP
in maintaining oxidative phosphorylation in a subset of AML
cells.
Loss of cell viability was not associated with changes in the
mtUPR markers Hsp70 or CPN60 or changes in mitochondrial
mass or structure in AML cell lines (Figures S3D–S3H).
A Small-Molecule ClpP Inhibitor Is Cytotoxic to AML
Cells
Recently, b-lactone inhibitors of bacterial ClpP were developed
and shown to be toxic to several bacterial species (Zeiler et al.,
2012). As a chemical approach to evaluate the effects of
ClpP inhibition on AML and normal cells, we synthesized the
reported bacterial ClpP inhibitor (3RS,4RS)-3-(non-8-en-1-yl)-
4-(2-(pyridin-3-yl)ethyl)oxetan-2-one (A2-32-01) (Figure S4A).
A2-32-01 inhibited the enzymatic activity of recombinant bac-
terial ClpP similarly as the activity of the b-lactone inhibitors
in the initial study (Zeiler et al., 2012; Figure S4B) as well as
the enzymatic activity of recombinant human mitochondrial
ClpP (Figure 5A). In addition, A2-32-01 inhibited cleavage of
ClpP fluorogenic peptide substrates when added to lysates
of mitochondria isolated from AML cells or intact AML cells
(Figure 5B). A2-32-01 did not inhibit cytoplasmic chymotrypsin,
trypsin, or caspase-like protease enzymatic activity when
added to lysates of red blood cells that contained proteasome
complexes but lacked mitochondria, therefore demonstrating
its specificity for mitochondrial proteases (Figure S4C).
A2-32-01 induced cell death in TEX, OCI-AML2, and K562 leu-
kemia cells at concentrations that matched its ability to inhibit
ClpP activity, but was not toxic to HL60 leukemia cells, which ex-
press much lower levels of ClpP (Figures 5C and 5D). However,
HL60 cells were more sensitive to the proteasome inhibitor borte-
zomib (Figure S4D). Similar toClpP shRNA, A2-32-01 reduced the
growth and viability of WT 143B cells but had little effect on the
growth and viability of their Rho (0) counterparts (Figure 5E).More-
over, addition of A2-32-01 to OCI-AML2 cells produced no addi-
tional loss of growth and viability after knockdown of ClpP (Fig-
ure S4E). We also evaluated analogs of A2-32-01. The related
compound A2-58-06 had activity similar to A2-32-01, whereas
A2-54-01 did not inhibit ClpP and did not reduce the growth and
viability of TEX and OCI-AML2 cells (Figures S4F and S4G).
Although A2-32-01 was stable in DMSO, it was rapidly hydro-
lyzed when dissolved in cell culture medium, with >90% of the
compound degraded within 1 hr (Figure S4H). We confirmed
that degradation products were inactive (data not shown). This
rapid degradation likely explains the high half-maximal inhibitory
concentration (IC50) of the compound.
Next we assessed the impact of A2-32-01 on primary AML and
normal hematopoietic cells. A2-32-01 showed significant dose-
dependent killing of primary AML patient cells that expressed
elevated levels of ClpP. In contrast, the same treatment had little
effect on either normal hematopoietic cells or primary AML cells
that expressed lower levels of ClpP (Figures 6A–6C). In fact, pri-
mary AML cells showed a strong positive correlation between
ClpP expression and sensitivity to A2-32-01 (Figure 6D). There-
fore, ClpP expression might serve as a biomarker for patients
who would respond to ClpP inhibitors.
A2-32-01 Shows Anti-AML Activity in Xenograft Models
of Human Leukemia
Finally, we evaluated the anti-leukemia efficacy and toxicity of
A2-32-01 in mouse models of leukemia. Dissolving A2-32-01 in
corn oil preserved its stability while in solution, and the pharma-
cokinetics of A2-32-01 were determined after intraperitoneal
(i.p.) injection of the compound into SCID mice (Figures S5A
and S5B). Next, we evaluated the efficacy and toxicity of A2-
32-01 in mice xenografted with OCI-AML2 cells. Daily treatment
with A2-32-01 delayed the growth of OCI-AML2 cells in SCID
mice without evidence of liver, muscle, or renal toxicity (Fig-
ure 7A; Figures S5C and S5D). Moreover, tumors excised from
mice treated for 5 days with A2-32-01 had reduced respiratory
chain complex II activity compared with vehicle-treated controls(Figure 7B) and reduced enzymatic activity of ClpP (Figure 7C).
Therefore, A2-32-01 inhibits growth and mitochondrial function
of this AML cell line in vivo.
We also assessed the efficacy and toxicity of A2-32-01 in
NOD-SCID mice engrafted intra-femorally with primary AML
cells. A2-32-01 treated mice had significantly lower levels of
leukemic engraftment compared to control-treated mice without
evidence of toxicity (Figure 7D). Thus, inhibiting ClpP may be an
effective strategy for a subset of AML patients.
DISCUSSION
The therapy for AML has remained largely unchanged over the
last 20 years, and the outcome for most patients is poor. In
search of more effective approaches, we found recently that
blocking mitochondrial protein translation was selectively cyto-
toxic to AML cells (Skrtic et al., 2011). This followed the discovery
that a subset of AML cells have unique mitochondrial character-
istics with increased mitochondrial biogenesis and increased
reliance on oxidative phosphorylation that could be inhibited
by targeting mitochondrial protein translation (Lagadinou et al.,
2013; Skrtic et al., 2011). Here we identify ClpP as a potential
component of the mitochondrial proteome whose inhibition
might be cytotoxic to AML cells. We found that ClpP is overex-
pressed in leukemic cells from a group of AML patients and
that inhibition of ClpP selectively induces death in these cells
without apparent toxicity to normal hematopoiesis. The fact
that increased expression of ClpP occurs across all currently
defined subtypes of AML based on their morphologic, cytoge-
netic, or mutational features, including those with a poor prog-
nosis, lends further support to the possibility that ClpP may be
an important therapeutic target for the treatment of AML. In addi-
tion, ClpP expression may be a useful biomarker to identify pa-
tients most likely to respond to ClpP inhibitors.
Little is known about the endogenous proteins that interact
with ClpP in the mitochondria of mammalian cells. Here we
identified that most of the proteins interacted with ClpP were
components of the respiratory chain and mitochondrial meta-
bolic enzymes. It is noteworthy that a similar set of ClpP sub-
strates, including the respiratory chain complex component
SDHA, were identified by Haynes et al. (2010) in their studies
of ClpP function in C. elegans. Therefore, ClpP appears to func-
tion to maintain the integrity of the respiratory chain and mito-
chondrial metabolism.
In C. elegans, peptides generated by ClpP-mediated protein
degradation are exported from the mitochondria via the trans-
porter haf-1 and signal the mtUPR response in the nucleus (Hay-
nes et al., 2007, 2010). Upon mitochondrial stress, levels of ClpP
and mtUPR-associated genes increase. To date, the mecha-
nisms by which ClpP regulates the mtUPR in mammalian cells
remain unknown, and the mammalian homolog of haf-1 has
not yet been defined.
In our study, gene expression analysis demonstrated that
higher levels of ClpP were associated with greater expression
of genes associated with the mtUPR. Because of increased
mitochondrial mass, high metabolic and biosynthetic require-
ments, and imbalances between levels of nuclear andmitochon-
drial encoded proteins, we hypothesize that the mitochondria in
a subset of AML and other cancer cells are under increasedCancer Cell 27, 864–876, June 8, 2015 ª2015 Elsevier Inc. 869
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Figure 4. ClpP Regulates Mitochondrial Metabolism
(A) Network of proteins that interacted with WT or catalytically inactive ClpP.
(B) Effects of ClpP knockdown on basal oxygen consumption (OCR) in OCI-AML2 cells 4 days after transduction with ClpP shRNA or control sequences.
Mean ± SD cell counts from one of three representative experiments are shown.
(C) Effects of ClpP knockdown on complex II activity in OCI-AML2 cells 4 days after transduction with ClpP shRNA or control sequences. The percent mean ± SD
enzymatic activity from one of three representative experiments is shown.
(D) Effects of ClpP knockdown onmitochondrial ROS production in OCI-AML2 cells 4 days after transduction with ClpP shRNA or control sequences. Mean ± SD
mitochondrial ROS-positive cells from one of three representative experiments are shown.
(legend continued on next page)
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Figure 5. A2-32-01 Inhibits ClpP and Is
Cytotoxic to AML Cells
(A) Effect of A2-32-01 on the ability of recombinant
human ClpP and ClpX to cleave the fluorogenic
substrate casein-FITC (mean ± SD). RFU, relative
fluorescence unit.
(B) Effect of A2-32-01 onClpP activity measured in
mitochondrial lysates from OCI-AML2 and TEX
cells after 2 hr basedoncleavage of the fluorogenic
substrate Suc-LY-AMC (percent mean ± SD).
(C)Effectof 48-hrA2-32-01 treatmenton theactivity
of ClpP in HL60, K562, OCI-AML2, and TEX cells
based on the cleavage of the fluorogenic substrate
Suc-LY-AMC. Normalized data are shown.
(D) Effect of 48-hr A2-32-01 treatment on the
viability of HL60, K562, OCI-AML2, and TEX cells.
The percent mean ± SD of viable cells was
measured by trypan blue staining.
(E) Effect of 48-hr A2-32-01 treatment on the
viability of WT and Rho (0) 143B cells. The percent
of viable cells was measured by trypan blue
staining.
See also Figure S4.basal stress and have upregulated ClpP in response to these
stressors. In support of this hypothesis, induction of mitochon-
drial protein aggregates through the overexpression of mutant
OTC in COS-7 cells inducedmtUPR and increased ClpP expres-
sion (Zhao et al., 2002).
Mechanisms that regulate ClpP expression in AML cells are
unknown and are an important direction for future study. In
COS-7 cells, the expression of ClpPmay be regulated at the level
of its promoter by a combination of CHOP, MURE1, and MURE2
sequences (Aldridge et al., 2007). However, it is unknown
whether these sequences also regulate ClpP expression in
AML cells, and the transcription factors that bind these sites
are unknown. In addition, regulation of ClpP may also occur at
the level of protein translation and degradation.
We used the bacterial ClpP inhibitor A2-32-01 to examine the
impact of inhibiting mitochondrial ClpP in AML because the
compound cross-reacted with the mitochondrial isoform. How-
ever, it is important to note that the selectivity of A2-32-01 for
mitochondrial ClpP over other mammalian targets, including
other mitochondrial proteases, remains to be determined. In
addition, A2-32-301 has poor stability in aqueous media, so
this molecule would not have therapeutic applications, and its
ability to reduce large bulk disease may be limited. Developing(E) Effect of ClpP knockdown in OCI-AML2 cells 4 days after infection with virus expressing shRNA targeting C
migration on a native gel determined by immunoblotting.
(F) Expression of ClpP in total cell lysates prepared from WT and Rho (0) 143B and OCI-AML2 cells.
(G and H) The expression of ClpP and b-actin were detected by immunoblotting in WT (G) and Rho (0) 143B (H
ClpP or control sequences.
(I) The number of viable WT and Rho (0) 143B cells was measured by trypan blue staining 12 days after tran
representative experiments showing the percent mean ± SD viable cells relative to cells infected with contro
See also Figure S3 and Table S2.
Cancer Cell 27, 864–potent, stable, and specific ClpP inhibi-
tors based on alternate scaffolds is a pri-
ority to fully assess the efficacy and
toxicity of ClpP inhibition in vivo.In AML cells, loss of viability after inhibition of ClpP was asso-
ciated with impairment of mitochondrial metabolism and oxida-
tive phosphorylation. This finding is consistent with prior studies
demonstrating that AML cells and stem cells have an increased
reliance on oxidative phosphorylation (Skrtic et al., 2011; Laga-
dinou et al., 2013). The fact that elevated ClpP expression was
not associated with any known molecular or clinical feature of
AML is consistent with this variable phenotype and suggests
that increased ClpP expression may be a consequence of multi-
ple dysregulated pathways that converge to impact mitochon-
drial function and metabolism.
In addition to ClpP, our shRNA screen of the mitochondrial
proteome identified three other mitochondrial proteases
whose knockdown reduced the growth and viability of K562
cells (NLN, PARL, and PITRM1). Little is known about mito-
chondrial proteases as cancer targets and the impact of in-
hibiting select mitochondrial proteases in malignant cells.
Potentially, these proteases could also be important thera-
peutic targets for AML given their role in regulating mitochon-
drial function. For example, PARL regulates PINK1 turnover,
and knockdown of PARL promotes accumulation of PINK1
on the mitochondrial surface, leading to increased mitophagy
(Greene et al., 2012). However, further studies will belpP or control sequences on SDHA expression and
) cells transduced with individual shRNA targeting
sduction as described in (F) and (G). One of three
l shRNA is presented.
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Figure 6. ClpP Expression Correlates with
Sensitivity to A2-32-01 in Primary AML Cells
(A) Expression of ClpP and Actin in primary normal
hematopoietic cells, primary AML patient sam-
ples, and OCI-AML2 cells was determined by
immunoblotting.
(B and C) Effect of A2-32-01 on the viability of
primary normal hematopoietic cells (B) and pri-
mary AML cells (C) assessed after a 48-hr period
of exposure. Themean ± SD percent of viable cells
was measured by Annexin V/propidium iodide (PI)
staining and flow cytometry.
(D) Correlation analysis of ClpP expression and
cell viability of primary AML cells. Cell viability was
measured by Annexin-V/PI staining 48 hr after
treatment with 80 mM of A2-32-01.necessary to fully understand the efficacy and toxicity of in-
hibiting PARL and other mitochondrial proteases in vitro
and in vivo.
Therefore, in summary, although AML may have significant
molecular and genetic heterogeneity, the dysregulation of
some biological pathways such as mitochondrial function and
metabolism remain common and may be amenable to therapeu-
tic exploitation.
EXPERIMENTAL PROCEDURES
See Supplemental Experimental Procedures for additional experimental
procedures.
shRNA Screen to Identify Targets in the Mitochondrial Proteome
To identify shRNA that reduced the growth and viability of AML cells, we per-
formed a pooled lentiviral shRNA screen in K562 cells similar to one
described previously (Ketela et al., 2011). K562 cells were selected because
of their robust transduction efficiencies, and their reliance on BCR-ABL1
signaling served as a positive control for the screen. K562 leukemia cells
were transduced with a pooled lentiviral library consisting of 54,021 shRNAs
in barcoded lentiviral vectors with puromycin selection markers targeting
11,255 nuclearly encoded genes. Of these, 34,600 were associated with
known genes and transcripts. These sequences were considered in the anal-
ysis. Cells were transduced at a multiplicity of infection of 0.3, ensuring that
each cell receives at most one shRNA. The day after infection, cells were
treated with puromycin to select infected cells. Resistant clones, containing
a lentiviral vector and its associated shRNA, were then grown in puromy-
cin-containing medium for 21 days. After 21 days, cells were harvested,
genomic DNA was isolated, and the abundance of barcoded sequences
was identified by microarray analysis. In conducting our lentiviral shRNA,
we performed two independent experiments utilizing the same amount of vi-
rus for transduction (inter-experiment or biological replicates). Each trial was872 Cancer Cell 27, 864–876, June 8, 2015 ª2015 Elsevier Inc.analyzed in duplicate on arrays (intra-experiment
or technical replicates), leading to the generation
of four replicates (two biological and two tech-
nical) for the 0- and 21-day time points.
Log2 background-corrected fluorescence sig-
nal intensities were compared pairwise for all
intra- and inter-experimental replicates at 0 and
21 days to ensure technical and experimental
reproducibility. Correlation coefficients for all pair-
wise comparisons were r2 > 0.97. Therefore, all
four technical and experimental replicates for
each time point were averaged to compare the
0- and 21-day time points. Fold changes were
computed by calculating the difference in meanLog2 (background-corrected fluorescence signal intensities) for each individ-
ual shRNA as follows:
Log2ðfold­changeÞ= Log2

mean intensityt=21 days

­Log2

mean intensityt= 0 days

:
Negative values indicated potential depletion of the individual shRNA.
A percent depletion value was also calculated as follows: % depletion =
(1–2Log2
(fold-change)) 3 100%.
shRNAs in the screen were ranked based on Log2(fold change) and percent
depletion values. shRNAswere also grouped by target gene to assess whether
multiple shRNAs targeting the same gene had high percent depletion scores.
Genes encoding the mitochondrial proteome were identified using MitoCarta
(http://www.broadinstitute.org/pubs/MitoCarta/).
Reverse-Phase Protein Array
A reverse phase protein array (RPPA) was generated by using samples
from patients with AML, myelodysplastic syndrome (MDS), and normal
CD34+ cells as described previously (Kornblau and Coombes, 2011; Korn-
blau et al., 2010, 2011; Pierce et al., 2013; Tibes et al., 2006). The ClpP
antibody was validated for use in the RPPA assay as described previously
(Kornblau and Coombes, 2011; Kornblau et al., 2010, 2011; Pierce et al.,
2013; Tibes et al., 2006). Briefly, the rabbit monoclonal ClpP antibody
(clone ab124822, Abcam) was validated to recognize only a single band
corresponding to the expected molecular weight by immunoblotting. In
addition, the sensitivity of the antibody in the RPPA assay was validated
using an array of cell line lysates seeded in serials dilutions. The RPPA
signal was linear over the range of dilutions. In addition, the signal obtained
with cell lysate dilutions by RPPA correlated with the signal intensity by
observed by immunoblotting (R2 = 0.75). When the RPPA was optimized
for detection of ClpP expression, patient and normal samples were printed
in five serial dilutions onto slides along with normalization and expression
controls. Slides were probed with anti-ClpP primary antibody (Abcam, cat-
alog no. 124822) at 1:1,000 and a secondary antibody followed by colori-
metric assay. Stained slides were analyzed using Microvigene software
(Vigene Tech).
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Figure 7. A2-32-01 Shows Anti-AML
Activity in Xenograft Models of Human
Leukemia
(A) Effect of i.p. injection of 300 mg/kg of A2-32-01
or corn oil vehicle control twice daily for 5 of 7 days
on tumor volume when OCI-AML2 cells were
xenografted into SCID mice (n = 10 mice/group).
Mean ± SD, ***p < 0.001 by t test.
(B) Respiratory chain complex II activity in tumors
from SCID mice xenografted with OCI-AML2 cells
and treated with i.p. injection of 300 mg/kg A2-32-
01 or corn oil vehicle control daily for 5 days (n = 4
mice/group). *p = 0.03 by t test. Horizontal bars
indicate the mean.
(C) ClpP activity measured by the cleavage of
the fluorogenic substrate casein-FITC in mito-
chondrial lysates in tumors from SCID mice xen-
ografted with OCI-AML2 cells and treated with i.p.
injection of 300 mg/kg A2-32-01 or corn oil vehicle control daily for 4 days (n = 9 mice/group). *p = 0.005 by t test. Horizontal bars indicate the mean.
(D) Human leukemia cell engraftment in sublethally irradiated female NOD/SCID mice and treated with A2-32-01 (300 mg/kg by i.p. injection daily) or vehicle
control (n = 10 mice/group) 3 of 7 days for 4 weeks was measured by flow cytometric analysis. Shown are results from two independent experiments. *p = 0.02
and **p < 0.0001 by t test. Horizontal bars indicate the mean.
See also Figure S5.Primary AML and Normal Hematopoietic Cells
Primary mononuclear cells were isolated from peripheral blood samples
from consenting patients with AML whose blast count was 80% or higher by
low-density cells isolated by Ficoll density centrifugation. Granulocyte col-
ony-stimulating factor (G-CSF)-mobilized peripheral blood stem cells were
obtained from healthy consenting volunteers donating peripheral blood stem
cells for allogeneic stem cell transplantation. All primary cells were cultured
at 37C in Iscove’s modified Dulbecco’s medium (IMDM) supplemented with
20% fetal bovine serum (FBS) and penicillin-streptomycin. Informed consent
was obtained from all subjects for the collection and use of samples. The
collection and use of human tissue for this study were approved by the Univer-
sity Health Network Institutional Review Board and Review Ethics Board of the
University of British Columbia.
shRNA Knockdown of ClpP
Construction of hairpin-pLKO.1 vectors (carrying a puromycin antibiotic
resistance gene) containing shRNA sequences and production of shRNA
viruses was performed as described previously (Simpson et al., 2012). The
shRNAs targeting the ClpP (accession no. NM_003321) coding sequence
are as follows: ClpP shRNA1, 50-GCCCATCCACATGTACATCAA-30; ClpP
shRNA2, 50-CACGATGCAGTACATCCTCAA30; and ClpP shRNA3, 50-
GCTCAAGAAGCAGCTCTATAA30.
Lentiviral transduction was performed essentially as described previously
(Xu et al., 2010). Briefly, cells (5 3 106) were centrifuged and resuspended in
5 ml of medium containing protamine sulfate (5 mg/ml). 0.5 ml of virus (for
adherent cells) and 2 ml of virus (for suspension cells) were added to the cells,
followed by overnight incubation (37C, 5% CO2). Cells were centrifuged and
washed, and fresh medium with puromycin (1mg/ml) was added the following
day. Three days later, cells were cultured to measure viability and growth.
Equal numbers of TEX cells transduced with shRNA targeting ClpP or
control sequences (2 3 105) were injected into the right femur of sublethally
irradiated NOD/SCID-GF mice with human transgenes producing inter-
leukin-3 (IL-3), granulocyte/macrophage-stimulating factor (GM-CSF), and
Steel factor (SF) (n = 10/group) (Nicolini et al., 2004). 6 weeks after injection,
mice were sacrificed, and the percentage of human CD45+ cells in the non-
injected left femur was determined by flow cytometry.
Evaluation of Hematopoietic Progenitors in WT and Clpp–/– Mice
Heterozygous Clpp knockout mice (C57BL/6N background) were obtained
from the Texas A&M Institute for Genomic Medicine, and breeding pairs
were established in our facility. Studies withClpp /mice were carried out ac-
cording to the regulations of the Canadian Council on Animal Care and with the
approval of the Ontario Cancer Institute and BC Cancer Agency animal ethics
review boards.Hematopoietic cells were flushed from the femora and tibiae of Clpp+/+ and
Clpp /mice using DMEM and 2% fetal calf serum (FCS) and passed through
a 70 mM strainer. The population was enriched for lineage-negative (Lin) pro-
genitor cells using magnetic bead separation (lineage cell depletion kit, Milte-
nyi). Cells (1-23 106) were preincubated with an Fc block for 10min at 4C and
immunostained with antibodies recognizing Sca1 (D7) and cKit (2B8) (both
from eBioscience). Flow cytometry data were acquired using a FACSCanto
II (BD Biosciences) flow cytometer and analyzed with the FlowJo analysis
program.
W41/W41CD45.1 sublethally irradiated (400 rad)micewere transplantedwith
106 CD45.2 hematopoietic cells from the femora of WT or Clpp/ mice along
with 106 competitor CD45.1 hematopoietic cells. Cells from two Clpp+/+ WT
mice were pooled and injected into five recipient CD45.1 mice. Cells from
each of three Clpp/ mice were injected into four to six CD45.1 recipients.
Peripheral blood samples were collected from the tail vein of recipient mice
5, 8, and 12 weeks after transplantation. Following lysis of the red blood cells
with ammonium chloride (StemCell), the white blood cells (WBCs) were stained
with antibodies for donor and recipient CD0.45 allotypes: anti-CD45.1-PECy7
(eBioscience) and anti-CD45.2-APCef780 (eBioscience) plus CD19BV421
(BioLegend) for B cells, Ly6G-PE and Mac-1-PE (both BD Pharmingen) for
myeloid cells, and CD3e-APC (BioLegend) for T cells. To calculate repopula-
tion levels, the contributions of the donor CD45.2-positive cells to the popula-
tions of circulating GM, B, and T cells and total WBCs were calculated.
To examine T cell function in Clpp/ and Clpp+/+ mice, 5 3 106 spleno-
cytes/well were seeded in wells coated with 3 mg/ml hamster anti-mouse
CD3 (clone 2C11-145, BD Biosciences) and 1 mg/ml hamster anti-mouse
CD28 (clone 37.51, eBioscience) for 24 hr. For B cell activation, splenocytes
(5 3 106/well) were cultured for 24 hr with 10 mg/ml goat anti-mouse immuno-
globulin M (IgM) (F(ab’)2 fragment, Jackson ImmunoResearch). To assess
activation status, cells were stained with fluorescence-conjugated antibodies
against surface markers. Flow cytometry data were acquired using a FACS-
Canto II (BD Biosciences) flow cytometer and analyzed with the FlowJo
analysis program.
BioID-MS to Identify ClpP-Interacting Proteins
Stable 293 T-REx cell pools expressing tetracycline-regulated, BirA*-tagged
WT, or catalytically inactive mutant ClpP proteins were generated. Cell pools
expressing the BirA* epitope tag alone or BirA* fused to the unrelated mito-
chondrial enzyme OTC were also created for use as negative controls. 293
T-REx cells (at 60% confluence) were treated with 1 mg/ml tetracycline and
50 mM biotin for 24 hr to induce transgene expression and effect biotinylation
of nearby polypeptides. Cells were scraped into PBS, pooled, washed twice in
25 ml PBS, and collected by centrifugation at 1000 3 g for 5 min at 4C. Cell
pellets were lysed in 5 ml ice-cold modified RIPA buffer. 250 U benzonaseCancer Cell 27, 864–876, June 8, 2015 ª2015 Elsevier Inc. 873
(EMDMillipore) was added, and biotinylated proteins were isolated. The result-
ing supernatant was incubated with 30 ml of (RIPA-equilibrated) streptavidin-
Sepharose beads (GE Healthcare) with end-over-end rotation for 2 hr at 4C.
Beads were washed seven times with 1 ml of 50 mM ammonium bicarbonate
(pH 8.0) prior to tryptic digestion.
Mass Spectrometry to Identify ClpP-Interacting Proteins
One microgram of MS-grade L-(tosylamido-2-phenyl) ethyl chloromethyl
ketone (TPCK) trypsin (Promega) dissolved in 70 ml of 50 mM ammonium
bicarbonate (pH 8.3) was added to the streptavidin-Sepharose beads and
incubated at 37C overnight. The eluate was collected, and beads were
washed twice in 100 ml of 50 mM ammonium bicarbonate. The combined
eluate was lyophilized and then resuspended in 0.1% formic acid. Liquid
chromatography (LC) analytical columns (75-mm inner diameter) and pre-col-
umns (150-mm inner diameter) were made in-house from fused silica capillary
tubing from InnovaQuartz and packed with 100 A˚ C18-coated silica particles
(Magic, Michrom Bioresources). Peptides were subjected to nano liquid
chromatography-electrospray ionization-tandem mass spectrometry (LC-
ESI-MS/MS) using a 95-min reverse-phase (10%–30% acetonitrile, 0.1%
formic acid) buffer gradient running at 250 nl/min on a Proxeon EASY-nLC
pump in-line with a hybrid linear quadrupole ion trap (Velos LTQ) Orbitrap
mass spectrometer (Thermo Fisher Scientific). A parent ion scan was per-
formed in the Orbitrap using a resolving power of 60,000. Simultaneously,
the 20 most intense peaks were selected for MS/MS (minimum ion count of
1,000 for activation) using standard collision-induced dissociation (CID) frag-
mentation. Fragment ions were detected in the LTQ. Dynamic exclusion was
activated so that MS/MS of the same mass to charge ratio (m/z) (within a 10-
ppm window, exclusion list size 500) detected two times within 15 s were
excluded from analysis for 30 s.
For protein identification, Thermo.RAW files were converted to the .mzXML
format using Proteowizard as part of the trans-proteomic pipeline (Keller and
Shteynberg, 2011). For each search, the iProphet probability at a 1% error
rate was used as a cutoff value to generate statistical analysis of interactomes
(SAINT)-compatible input files. SAINT parameters were as follows: 5,000 iter-
ations, low mode off, minFold 1, and normalization on Choi et al., 2011).
Via the ProHits suite (Liu et al., 2010, 2012), MS data were analyzed using the
X!Tandem database search algorithm, and the resulting peptide identifications
were subjected to iProphet analysis (Shteynberg et al., 2011) within the trans-
proteomic pipeline (Keller and Shteynberg, 2011). Using BirA*-only cell data as
a control for endogenous biotinylated proteins and polypeptides that interact
non-specifically with the solid phase support, the BirA*-ClpP data were sub-
jected to SAINT (Choi et al., 2011) to identify bona fide interacting partners.
Polypeptides identified with an iProphet confidence value of >0.8 (reflecting
an 1% error rate) and assigned a maximum SAINT confidence value of
>0.80 are shown in Figure S3A.
The network of proteins that interacted withWT or catalytically inactive ClpP
preferentially over OTC or empty vector were defined using GeneMANIA 3.3.1,
Cytoscape 3.1.0 (Montojo et al., 2010). Preferential interactions comparedwith
OTC or empty vector were identified in 293 T-REx cells using the BirA* tagging
method.
Bacterial and Human ClpP Activity
Bacterial ClpP was purified from E. coli as described previously (Kimber et al.,
2010). To measure ClpP peptidase activity, 1 mM ClpP (monomer concentra-
tion) was dissolved in assay buffer (50 mM Tris-Cl [pH 8.0], 200 mM KCl,
and 1 mM DTT) with 0.5 mM succinyl-leucine-tyrosine-7-amino-4-methylcou-
marin (Suc-LY-AMC). This mixture was then plated at 50 ml/well in a 96-well
plate and read for fluorescence at 2-min intervals for 1 hr at 360/460 nm.
The rate of ClpP was determined by calculating the slope (in the linear range).
Human recombinant ClpP (1.2 mM) and ClpX (1.0 mM) were combined and
dissolved in assay buffer consisting of 25 mM N-2-hydroxyethylpiperazine-
N’-2-ethanesulfonic acid (HEPES) (pH 7.5), 5 mM MgCl2, 5 mM KCl, 0.03%
Tween 20, and 10% glycerol with an ATP regeneration system of 16 mM
creatine phosphate and 13 U/ml creatine kinase. 3 mM ATP was added along
with the ClpX substrate, casein-fluorescein isothiocyanate (FITC, 4.5 mM). All
components were mixed and covered from light at 37C for 5 min. The mixture
was then plated at 200 ml/well in triplicates in a 96-well plate with or without
ClpP inhibitors. Fluorescence at 485/535 nm was measured at 37C every874 Cancer Cell 27, 864–876, June 8, 2015 ª2015 Elsevier Inc.10 min for 6 hr. The rate of ClpP activity was determined by calculating the
slope (in the linear range).
Purification of Human ClpP and ClpX
Plasmids encoding human ClpP and ClpX were transformed into B21 Gold
DE3 pLys and B21 Gold DE3 bacteria, respectively. Transformed bacteria
were plated on Luria broth (LB)-agar plates containing 100 mg/ml ampicillin
and incubated overnight at 37C. The following day, individual colonies were
grown overnight at 37C in LB medium containing 100 mg/ml ampicillin
(ClpP) or 85 mg/ml chloramphenicol and 100 mg/ml ampicillin (ClpX). ClpP
and ClpX expression were induced with 1mM isopropyl b-D-1-thiogalactopyr-
anoside (IPTG) in Terrific medium without antibiotics. Bacteria were collected
after 4 hr, and the pellet was frozen at 70C. ClpP and ClpX proteins were
purified on Ni-agarose using lysis buffer (25 mM Tris-HCl [pH 7.5], 500 mM
NaCl, 10% Glycerol, 5 mM mercaptoethanol, and 10 mM imidazole), wash
buffer (25 mM Tris-HCl [pH 7.5], 500 mM NaCl, 10% Glycerol, 5 mM mercap-
toethanol, and 50 mM imidazole), and elution buffer (25 mM Tris-HCl [pH 7.5],
500 mMNaCl, 10%Glycerol, 5 mMmercaptoethanol, and 250mM imidazole).
The proteins were dialyzed for 4 hr at 4C in dialysis buffer (50 mM Tris-HCl
[pH 7.5], 200 mM KCl, 25mM MgCl2, 10% g1ycerol, 1 mM DTT, and 0.1 mM
EDTA). The recombinant proteins were stored at 70C.
ClpP Activity in Isolated Mitochondria
Intact mitochondria from cell lines were isolated as described above. The flu-
orogenic substrate Suc-LY-AMC (0.5 mM) was added tomitochondrial lysates
in ClpP peptidase assay buffer (50 mM Tris-Cl [pH 8.0], 200 mM KCl, 1 mM
DTT, 0.1% n-dodecyl b-D-maltoside [DDM], and 2 mM ATP). This mixture
was plated at 50 ml/well in a 96-well plate, and fluorescence was measured
at 2-min intervals for 1 hr (360/460nm). The rate of ClpP activity was deter-
mined by calculating the slope (in the linear range).
Assessment of Anti-Leukemia Activity of A2-32-01 in MouseModels
of Human Leukemia
OCI-AML2 human leukemia cells (5 3 105) were injected subcutaneously into
the flanks of male SCIDmice (Ontario Cancer Institute). When the tumors were
palpable, mice were treated with A2-32-01 or vehicle control (corn oil) by i.p.
injection (300 mg/kg twice daily for 5 of 7 days) for 10 days (n = 10/group).
Tumor volume was measured using caliper measurements at the end of the
experiment. Mice were sacrificed, and organs were harvested, fixed with
10% buffered formalin, embedded, sectioned, and stained with H&E. The
stained samples were scanned using Aperio Scanscope XT at 103magnifica-
tion and analyzed using Aperio ImageScope.
To assess the effect of A2-32-01 on complex II activity in vivo, OCI-AML2
human leukemia cells (5 3 105) were injected subcutaneously into the flanks
of male SCID mice (Ontario Cancer Institute). When the tumors were palpable,
mice were treated with A2-32-01 or vehicle control (corn oil) by i.p. injection
(300 mg/kg daily) for 5 days (n = 4/group). After 5 days, tumors were excised,
and complex II activity was measured as above.
To assess A2-32-01 in mouse models of primary AML engraftment, a frozen
aliquot of AML cells was thawed, counted, and re-suspended in PBS, and
2.5 3 106 viable trypan blue-negative cells were injected into the right femur
of 10 week-old female NOD-SCID mice that had been irradiated 24 hr previ-
ously with 208 rad from a 137Cs source and injected with 200 mg anti-mouse
CD122. Two weeks after injection of AML cells, mice were treated with A2-
32-01 (300 mg/kg by i.p. injection) or vehicle control (n = 10/group) 3 of
7 days for 4 weeks. Mice were then sacrificed, and the cells were flushed
from the femora. Engraftment of human AML cells into the marrow of the
non-injected left femur was assessed by enumerating the percentage of
human CD45+CD33+CD19 cells by flow cytometry using the BD Biosciences
FACSCalibur. Data were analyzed with FlowJo version 7.7.1 (Tree Star).
All animal studies were carried out according to the regulations of the Cana-
dian Council on Animal Care and with the approval of the Ontario Cancer Insti-
tute animal ethics review board.
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SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.ccell.2015.05.004.
ACKNOWLEDGMENTS
We thank Urlich Baxa (Electron Microscopy Laboratory, NCI [NIH]) for help
with electron microscopy, Aisha Shamas-Din (Princess Margaret Cancer
Centre) for help with preparing the manuscript, and Jill Flewelling (Princess
Margaret Cancer Centre) for administrative assistance. This work was
supported by the Canadian Stem Cell Network, the Leukemia and Lymphoma
Society, the NIH (NCI 1R01CA157456), the Canadian Institutes of Health
Research, a Terry Fox Research Foundation Program Project Group Grant
(to C.J.E.), MaRS Innovation, the Ontario Institute for Cancer Research with
funding provided by the Ontario Ministry of Research and Innovation, the
Princess Margaret Cancer Centre Foundation, and the Ministry of Long
Term Health and Planning in the Province of Ontario. S.B. was supported by
a Vanier Scholarship award from CIHR. D.V.J. is a Fonds de recherche du
Que´bec – Sante´ (FRQS) postdoctoral scholar. A.D.S. holds the Barbara Baker
Chair in Leukemia and Related Diseases.
Received: November 4, 2014
Revised: February 6, 2015
Accepted: May 7, 2015
Published: June 8, 2015
REFERENCES
Aldridge, J.E., Horibe, T., and Hoogenraad, N.J. (2007). Discovery of genes
activated by the mitochondrial unfolded protein response (mtUPR) and
cognate promoter elements. PLoS ONE 2, e874.
Choi, H., Larsen, B., Lin, Z.Y., Breitkreutz, A., Mellacheruvu, D., Fermin, D.,
Qin, Z.S., Tyers, M., Gingras, A.C., and Nesvizhskii, A.I. (2011). SAINT: proba-
bilistic scoring of affinity purification-mass spectrometry data. Nat. Methods 8,
70–73.
Conlon, B.P., Nakayasu, E.S., Fleck, L.E., LaFleur, M.D., Isabella, V.M.,
Coleman, K., Leonard, S.N., Smith, R.D., Adkins, J.N., and Lewis, K. (2013).
Activated ClpP kills persisters and eradicates a chronic biofilm infection.
Nature 503, 365–370.
Corydon, T.J., Bross, P., Holst, H.U., Neve, S., Kristiansen, K., Gregersen, N.,
and Bolund, L. (1998). A human homologue of Escherichia coli ClpP caseino-
lytic protease: recombinant expression, intracellular processing and subcellu-
lar localization. Biochem. J. 331, 309–316.
Dan, S., Naito, M., and Tsuruo, T. (1998). Selective induction of apoptosis in
Philadelphia chromosome-positive chronic myelogenous leukemia cells by
an inhibitor of BCR - ABL tyrosine kinase, CGP 57148. Cell Death Differ. 5,
710–715.
de Sagarra, M.R., Mayo, I., Marco, S., Rodrı´guez-Vilarin˜o, S., Oliva, J.,
Carrascosa, J.L., and Casta n˜, J.G. (1999). Mitochondrial localization and olig-
omeric structure of HClpP, the human homologue of E. coli ClpP. J. Mol. Biol.
292, 819–825.
Fisher, R.I., Bernstein, S.H., Kahl, B.S., Djulbegovic, B., Robertson, M.J., de
Vos, S., Epner, E., Krishnan, A., Leonard, J.P., Lonial, S., et al. (2006).
Multicenter phase II study of bortezomib in patients with relapsed or refractory
mantle cell lymphoma. J. Clin. Oncol. 24, 4867–4874.
Gispert, S., Parganlija, D., Klinkenberg, M., Dro¨se, S., Wittig, I., Mittelbronn,
M., Grzmil, P., Koob, S., Hamann, A., Walter, M., et al. (2013). Loss of mito-
chondrial peptidase Clpp leads to infertility, hearing loss plus growth retarda-
tion via accumulation of CLPX, mtDNA and inflammatory factors. Hum. Mol.
Genet. 22, 4871–4887.
Goard, C.A., and Schimmer, A.D. (2014). Mitochondrial matrix proteases as
novel therapeutic targets in malignancy. Oncogene 33, 2690–2699.
Greene, A.W., Grenier, K., Aguileta, M.A., Muise, S., Farazifard, R., Haque,
M.E., McBride, H.M., Park, D.S., and Fon, E.A. (2012). Mitochondrial process-ing peptidase regulates PINK1 processing, import and Parkin recruitment.
EMBO Rep. 13, 378–385.
Haynes, C.M., Petrova, K., Benedetti, C., Yang, Y., and Ron, D. (2007). ClpP
mediates activation of a mitochondrial unfolded protein response in C.
elegans. Dev. Cell 13, 467–480.
Haynes, C.M., Yang, Y., Blais, S.P., Neubert, T.A., and Ron, D. (2010). The
matrix peptide exporter HAF-1 signals a mitochondrial UPR by activating the
transcription factor ZC376.7 in C. elegans. Mol. Cell 37, 529–540.
Jenkinson, E.M., Rehman, A.U., Walsh, T., Clayton-Smith, J., Lee, K., Morell,
R.J., Drummond, M.C., Khan, S.N., Naeem, M.A., Rauf, B., et al.; University of
Washington Center for Mendelian Genomics (2013). Perrault syndrome is
caused by recessive mutations in CLPP, encoding a mitochondrial ATP-
dependent chambered protease. Am. J. Hum. Genet. 92, 605–613.
Kang, S.G., Dimitrova, M.N., Ortega, J., Ginsburg, A., andMaurizi, M.R. (2005).
Humanmitochondrial ClpP is a stable heptamer that assembles into a tetrade-
camer in the presence of ClpX. J. Biol. Chem. 280, 35424–35432.
Keller, A., and Shteynberg, D. (2011). Software pipeline and data analysis for
MS/MS proteomics: the trans-proteomic pipeline. Methods Mol. Biol. 694,
169–189.
Ketela, T., Heisler, L.E., Brown, K.R., Ammar, R., Kasimer, D., Surendra, A.,
Ericson, E., Blakely, K., Karamboulas, D., Smith, A.M., et al. (2011). A compre-
hensive platform for highlymultiplexedmammalian functional genetic screens.
BMC Genomics 12, 213.
Kimber, M.S., Yu, A.Y., Borg, M., Leung, E., Chan, H.S., and Houry, W.A.
(2010). Structural and theoretical studies indicate that the cylindrical protease
ClpP samples extended and compact conformations. Structure 18, 798–808.
Kornblau, S.M., and Coombes, K.R. (2011). Use of reverse phase protein
microarrays to study protein expression in leukemia: technical and methodo-
logical lessons learned. Methods Mol. Biol. 785, 141–155.
Kornblau, S.M., Singh, N., Qiu, Y., Chen, W., Zhang, N., and Coombes, K.R.
(2010). Highly phosphorylated FOXO3A is an adverse prognostic factor in
acute myeloid leukemia. Clin. Cancer Res. 16, 1865–1874.
Kornblau, S.M., Qiu, Y.H., Zhang, N., Singh, N., Faderl, S., Ferrajoli, A., York,
H., Qutub, A.A., Coombes, K.R., and Watson, D.K. (2011). Abnormal expres-
sion of FLI1 protein is an adverse prognostic factor in acute myeloid leukemia.
Blood 118, 5604–5612.
Lagadinou, E.D., Sach, A., Callahan, K., Rossi, R.M., Neering, S.J.,
Minhajuddin, M., Ashton, J.M., Pei, S., Grose, V., O’Dwyer, K.M., et al.
(2013). BCL-2 inhibition targets oxidative phosphorylation and selectively
eradicates quiescent human leukemia stem cells. Cell Stem Cell 12, 329–341.
Liu, G., Zhang, J., Larsen, B., Stark, C., Breitkreutz, A., Lin, Z.Y., Breitkreutz,
B.J., Ding, Y., Colwill, K., Pasculescu, A., et al. (2010). ProHits: integrated soft-
ware for mass spectrometry-based interaction proteomics. Nat. Biotechnol.
28, 1015–1017.
Liu, G., Zhang, J., Choi, H., Lambert, J.P., Srikumar, T., Larsen, B., Nesvizhskii,
A.I., Raught, B., Tyers, M., and Gingras, A.C. (2012). Using ProHits to
store, annotate, and analyze affinity purification-mass spectrometry (AP-MS)
data. In Current Protocols in Bioinformatics (John Wiley & Sons), pp. 8.16.
1–18.16. 32.
Montojo, J., Zuberi, K., Rodriguez, H., Kazi, F., Wright, G., Donaldson, S.L.,
Morris, Q., and Bader, G.D. (2010). GeneMANIA Cytoscape plugin: fast gene
function predictions on the desktop. Bioinformatics 26, 2927–2928.
Nicolini, F.E., Cashman, J.D., Hogge, D.E., Humphries, R.K., and Eaves, C.J.
(2004). NOD/SCID mice engineered to express human IL-3, GM-CSF and
Steel factor constitutively mobilize engrafted human progenitors and compro-
mise human stem cell regeneration. Leukemia 18, 341–347.
O’Connor, O.A., Stewart, A.K., Vallone, M., Molineaux, C.J., Kunkel, L.A.,
Gerecitano, J.F., and Orlowski, R.Z. (2009). A phase 1 dose escalation study
of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzo-
mib (PR-171) in patients with hematologic malignancies. Clin. Cancer Res. 15,
7085–7091.
Pierce, A., Whetton, A.D., Meyer, S., Ravandi-Kashani, F., Borthakur, G.,
Coombes, K.R., Zhang, N., and Kornblau, S. (2013). TransglutaminaseCancer Cell 27, 864–876, June 8, 2015 ª2015 Elsevier Inc. 875
2 expression in acute myeloid leukemia: association with adhesion molecule
expression and leukemic blast motility. Proteomics 13, 2216–2224.
Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A.,
Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H.,
et al.; Assessment of Proteasome Inhibition for Extending Remissions
(APEX) Investigators (2005). Bortezomib or high-dose dexamethasone for
relapsed multiple myeloma. N. Engl. J. Med. 352, 2487–2498.
Roux, K.J., Kim, D.I., Raida, M., and Burke, B. (2012). A promiscuous biotin
ligase fusion protein identifies proximal and interacting proteins in mammalian
cells. J. Cell Biol. 196, 801–810.
Shteynberg, D., Deutsch, E.W., Lam, H., Eng, J.K., Sun, Z., Tasman, N.,
Mendoza, L., Moritz, R.L., Aebersold, R., and Nesvizhskii, A.I. (2011).
iProphet: multi-level integrative analysis of shotgun proteomic data improves
peptide and protein identification rates and error estimates. Mol. Cell.
Proteomics 10, http://dx.doi.org/10.1074/mcp.M111.007690.
Simpson, C.D., Hurren, R., Kasimer, D., MacLean, N., Eberhard, Y., Ketela, T.,
Moffat, J., and Schimmer, A.D. (2012). A genomewide shRNA screen identifies
a/b hydrolase domain containing 4 (ABHD4) as a novel regulator of anoikis
resistance. Apoptosis 17, 666–678.
Skrtic, M., Sriskanthadevan, S., Jhas, B., Gebbia, M., Wang, X., Wang, Z.,
Hurren, R., Jitkova, Y., Gronda,M., Maclean, N., et al. (2011). Inhibition ofmito-876 Cancer Cell 27, 864–876, June 8, 2015 ª2015 Elsevier Inc.chondrial translation as a therapeutic strategy for human acute myeloid leuke-
mia. Cancer Cell 20, 674–688.
Tibes, R., Qiu, Y., Lu, Y., Hennessy, B., Andreeff, M., Mills, G.B., and Kornblau,
S.M. (2006). Reverse phase protein array: validation of a novel proteomic
technology and utility for analysis of primary leukemia specimens and hemato-
poietic stem cells. Mol. Cancer Ther. 5, 2512–2521.
Vij, R., Wang, M., Kaufman, J.L., Lonial, S., Jakubowiak, A.J., Stewart, A.K.,
Kukreti, V., Jagannath, S., McDonagh, K.T., Alsina, M., et al. (2012). An
open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzo-
mib in bortezomib-naive patients with relapsed and/or refractory multiple
myeloma. Blood 119, 5661–5670.
Xu, G.W., Ali, M., Wood, T.E., Wong, D., Maclean, N., Wang, X., Gronda, M.,
Skrtic, M., Li, X., Hurren, R., et al. (2010). The ubiquitin-activating enzyme E1
as a therapeutic target for the treatment of leukemia and multiple myeloma.
Blood 115, 2251–2259.
Zeiler, E., Korotkov, V.S., Lorenz-Baath, K., Bo¨ttcher, T., and Sieber, S.A.
(2012). Development and characterization of improved b-lactone-based anti-
virulence drugs targeting ClpP. Bioorg. Med. Chem. 20, 583–591.
Zhao, Q., Wang, J., Levichkin, I.V., Stasinopoulos, S., Ryan, M.T., and
Hoogenraad, N.J. (2002). Amitochondrial specific stress response in mamma-
lian cells. EMBO J. 21, 4411–4419.
